Two New Types Of Childhood Leukemia Discovered
By LabMedica International staff writers Posted on 22 Jun 2016 |
Image: A blood film of a pediatric patient with B-cell precursor acute lymphoblastic leukemia (Photo courtesy of Dr. Peter Maslak, MD).
Acute lymphoblastic leukemia is a rare disease, but the most common form of cancer in children and nowadays the treatment is very successful, but requires intense interventions at the risk of causing many side effects.
There is therefore a need to distinguish between different types of acute lymphoblastic leukemia, in order to adapt the treatment according to the severity of each case, and to detect possible relapse. Previous studies of childhood acute lymphoblastic leukemia have shown that there are six major groups of acute lymphoblastic leukemia in children.
A large team of international scientists led by those at Lund University (Sweden) studied leukemia cells from more than 200 children using next-generation sequencing technology (NGS), and were able to study the genome of cancer cells, which is how they discovered the two new types of cancer. The discovered two new types, together representing about 10% of all childhood leukemia, can now be added to the other groups.
The investigators were able to delineate the fusion gene landscape in a consecutive series of 195 pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL). They used ribonucleic acid (RNA) sequencing, to find in-frame fusion genes in 127 (65%) cases, including 27 novel fusions. They describe a subtype characterized by recurrent IGH-DUX4 or ERG-DUX4 fusions, representing 4% of cases, leading to overexpression of DUX4 and frequently co-occurring with intragenic ERG deletions. They identified a subtype characterized by an ETV6-RUNX1-like gene-expression profile and coexisting ETV6 and IKZF1 alterations. The study provides a detailed overview of fusion genes in pediatric BCP ALL and added new pathogenetic insights, which may improve risk stratification and provide therapeutic options for this disease.
Thoas Fioretos, MD, PhD, a professor and principal investigator of the study said, “Like all types of cancer, childhood leukemia is caused by genetic mutations in normal cells, which are then transformed into cancer cells. Finding the critical mutations in the diseased cells are an important condition for understanding the mechanisms of the disease and ultimately discovering new therapies,” The study was published on June 6, 2016, in the journal Nature Communications.
Related Links:
Lund University
There is therefore a need to distinguish between different types of acute lymphoblastic leukemia, in order to adapt the treatment according to the severity of each case, and to detect possible relapse. Previous studies of childhood acute lymphoblastic leukemia have shown that there are six major groups of acute lymphoblastic leukemia in children.
A large team of international scientists led by those at Lund University (Sweden) studied leukemia cells from more than 200 children using next-generation sequencing technology (NGS), and were able to study the genome of cancer cells, which is how they discovered the two new types of cancer. The discovered two new types, together representing about 10% of all childhood leukemia, can now be added to the other groups.
The investigators were able to delineate the fusion gene landscape in a consecutive series of 195 pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL). They used ribonucleic acid (RNA) sequencing, to find in-frame fusion genes in 127 (65%) cases, including 27 novel fusions. They describe a subtype characterized by recurrent IGH-DUX4 or ERG-DUX4 fusions, representing 4% of cases, leading to overexpression of DUX4 and frequently co-occurring with intragenic ERG deletions. They identified a subtype characterized by an ETV6-RUNX1-like gene-expression profile and coexisting ETV6 and IKZF1 alterations. The study provides a detailed overview of fusion genes in pediatric BCP ALL and added new pathogenetic insights, which may improve risk stratification and provide therapeutic options for this disease.
Thoas Fioretos, MD, PhD, a professor and principal investigator of the study said, “Like all types of cancer, childhood leukemia is caused by genetic mutations in normal cells, which are then transformed into cancer cells. Finding the critical mutations in the diseased cells are an important condition for understanding the mechanisms of the disease and ultimately discovering new therapies,” The study was published on June 6, 2016, in the journal Nature Communications.
Related Links:
Lund University
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data